中华皮肤科杂志 ›› 2026, e20260309.doi: 10.35541/cjd.20260309

• 指南与共识 • 上一篇    

中国肛门生殖器疣临床管理指南(2026版)

中国医师协会皮肤科医师分会性传播疾病专业委员会   

  1. 中国医师协会皮肤科医师分会性传播疾病专业委员会
  • 收稿日期:2026-06-01 修回日期:2026-10-04 发布日期:2026-11-09
  • 通讯作者: 徐金华;陆小年;周平玉;王千秋 E-mail:xjhhsyy@163.com; luxiaonian@fudan.edu.cn; zhoupingyu@medmail.com.cn; doctorwqq@163.com

2026 Chinese Guideline for the Clinical Management of Anogenital Warts

Committee on Sexually Transmitted Diseases, China Dermatologist Association   

  1. Committee on Sexually Transmitted Diseases, China Dermatologist Association
  • Received:2026-06-01 Revised:2026-10-04 Published:2026-11-09
  • Contact: Xu Jinhua; Lu Xiaonian; Zhou Pingyu; Wang Qianqiu E-mail:xjhhsyy@163.com; luxiaonian@fudan.edu.cn; zhoupingyu@medmail.com.cn; doctorwqq@163.com

摘要: 【摘要】    肛门生殖器疣,又称尖锐湿疣,是由人乳头瘤病毒(HPV)感染所致的良性增生性病变,主要累及肛门生殖器区域皮肤与黏膜。该病传播性强,复发率高,显著影响患者生活质量,目前临床尚无根除HPV感染的特效抗病毒治疗。本指南由中国医师协会皮肤科医师分会性传播疾病专业委员会组织我国性传播疾病及相关领域专家联合制订,遵循指南研究与评价工具(AGREE)第2版国际指南开发规范并结合我国流行病学特征,旨在解决诊断挑战、治疗争议、管理难点等核心问题。规范化诊疗与全流程综合管理是本指南的核心:典型皮损可临床诊断,不典型或特殊部位需联合醋酸白试验、皮肤镜、阴道镜、肛门镜、尿道镜、HPV检测及病理检查,宫颈及肛内疣治疗前需排除癌前病变或癌变;应采取个体化、联合治疗策略清除疣体,重视亚临床感染干预以及潜伏感染的定期随访;疣体清除后随访6 ~ 9个月;针对妊娠、儿童、免疫缺陷等特殊人群实施差异化诊疗;推荐符合接种条件人群接种HPV疫苗,并开展性伴筛查和安全性行为教育。本指南为临床提供标准化诊疗路径,以提升临床规范化诊疗水平,完善疾病综合防控体系。

关键词: 尖锐湿疣, 肛门, 肛门生殖器疣, 人乳头瘤病毒, 临床管理, 诊疗指南

Abstract: 【Abstract】    Anogenital warts, also known as condylomata acuminata, are benign proliferative lesions caused by human papillomavirus (HPV) infection and primarily affect the skin and mucous membranes of the anogenital region. The disease is highly transmissible and has a high recurrence rate, significantly affecting patients' quality of life. Currently, no specific antiviral treatment is available to eradicate HPV infection. This guideline was developed by a panel of experts in sexually transmitted diseases and related fields in China, organized by the Committee on Sexually Transmitted Diseases, China Dermatologist Association. It was developed in accordance with the international guideline development standards of the Appraisal of Guidelines for Research and EvaluationⅡ (AGREEⅡ) and tailored to the epidemiological characteristics of China, aiming to address key issues, including diagnostic challenges, treatment controversies, and management difficulties. Standardized diagnosis and treatment, together with comprehensive management throughout the disease course, are the core principles of this guideline. Typical lesions can be diagnosed clinically, whereas atypical lesions or those involving special anatomical sites require a combination of diagnostic methods, including the acetic acid test, dermoscopy, colposcopy, anoscopy, urethroscopy, HPV testing, and histopathological examination. Precancerous lesions and malignancies should be ruled out before treating cervical or intra-anal warts. Individualized and combination treatment strategies should be adopted to remove visible warts, with particular attention to the management of subclinical infections and regular follow-up for latent infections. Follow-up is recommended for 6 - 9 months after wart clearance. Differential diagnostic and therapeutic approaches should be implemented for special populations, including pregnant women, children, and immunocompromised individuals. HPV vaccination is recommended for eligible populations, along with sexual partner screening and education on safer sexual practices. This guideline provides standardized diagnostic and therapeutic pathways for clinical practice, with the aim of improving the quality of standardized clinical care and strengthening the comprehensive disease prevention and control system.

Key words: Condylomata acuminata, Anus, Anogenital warts, Human papillomavirus, Clinical governance, Diagnostic and treatment guideline

引用本文

中国医师协会皮肤科医师分会性传播疾病专业委员会. 中国肛门生殖器疣临床管理指南(2026版)[J]. 中华皮肤科杂志, 2026,e20260309. doi:10.35541/cjd.20260309

Committee on Sexually Transmitted Diseases, China Dermatologist Association. 2026 Chinese Guideline for the Clinical Management of Anogenital Warts[J]. Chinese Journal of Dermatology,2026,e20260309. doi:10.35541/cjd.20260309